GSK Hep B Drug Shows 19% Cure Rate
GSK's bepirovirsen shows promise in hepatitis B trial with 19% functional cure rate, potentially impacting treatment options. This development may affect GSK's stock and the broader pharmaceutical sector.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.